ClinicalTrials.gg
RecruitingNCT06735144Updated Dec 5, 2025

Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors

A Phase 1/2 interventional study of FH-006 and FH-006 in Malignant Solid Tumor, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in subjects with advanced malignant solid tumors, and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), recommended dose for phase II clinical trials (RP2D), and preliminary efficacy.

02

Conditions studied

  • Malignant Solid Tumor
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women aged 18 to 75 (inclusive)
  2. Subjects with or cytologically confirmed recurrent or solid tumors who experience disease progression after standard treatment, or who do not have a standard treatment plan or are not suitable for standard treatment.
  3. score is 0 or 1
  4. An expected survival of ≥3 months
  5. At least one target lesion according to v1.1 criteria
  6. Has a good level of organ function
  7. Patients voluntarily joined the study and signed

Exclusion criteria

Exclusion Criteria:

  1. Have other within the past 5 years
  2. Active central nervous system without surgery or radiotherapy
  3. Presence with uncontrollable third space effusion
  4. Have undergone other anti-tumor treatment within 4 weeks before the first dose
  5. Has severe infection within 4 weeks before the first medication
  6. Any active disease or a history of autoimmune disease
  7. A history of immune deficiency
  8. Has serious cardiovascular and cerebrovascular diseases
  9. history of lung disease
  10. The toxicity from previous anti-tumor treatment has not recovered to ≤ grade I
  11. Having undergone surgery on important organs within 4 weeks prior to the first use of medication
  12. Used attenuated within 28 days prior to the first use of the drug
  13. Presence of other serious physical or mental diseases or laboratory abnormalities
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Queue A

    Drug: FH-006

  • Experimental
    Queue B

    Drug: FH-006

Interventions

  • DrugFH-006

    Intravenous injection once every two weeks (Q2W), with a treatment period of 28 days

  • DrugFH-006

    administered once every 3 weeks (Q3W), with a treatment period of 21 days

06

What researchers measure

Primary outcomes

  1. DLT: 21or28 days after the first administration of each subject

    Time frame: 21or28 days after the first administration of each subject

  2. AE: from Day1 to 30 days after last dose

    Time frame: from Day1 to 30 days after last dose

  3. Incidence and severity of serious adverse events (SAE): from Day1 to 30 days after last dose

    Time frame: from Day1 to 30 days after last dose

  4. MTD or MAD: 21 or 28 days after the first dose of medication for each subject on dose escalation stage

    Time frame: 21 or 28 days after the first dose of medication for each subject on dose escalation stage

  5. RP2D:Obtain two treatment evaluation data for the last subject during the dose expansion phase

    Time frame: Obtain two treatment evaluation data for the last subject during the dose expansion phase

Secondary outcomes

  1. Immunogenic indicators: anti-FH-006 antibody (ADA)

    Time frame: through study completion, an average of 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2024
First posted
Dec 16, 2024
StartActual
Dec 23, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06735144
Responsible party
Sponsor
First posted
Dec 16, 2024
Start date
Dec 23, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Dec 5, 2025

Study contacts

Xiaoxue Pi
Contact
Xiaoxue.pi@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FH-006

Start the discussion